



# Celemics Target Enrichment Kit & Service Features and Benefits

At Celemics, we support our customers with targeted capture-based NGS service and product elaborately designed and manufactured by experienced researchers and technicians. We have established a robust system for customized design panel and developed a variety of kits according to our customer needs. All Ready-to-use kits are completely validated and provide the best performance in the market. Our research team has extensive experience of designing and manufacturing over a thousand customized panels and guarantees the best quality product and service to our customers.


## Experience our full-support customization service




## Overcome limitations of NGS through our advanced technologies




## Benefit from our products and services optimized to your requirements



## Receive products and services with quality at the most affordable price in the market





# Customized Panel Manufacturing Process



## Exceptional Panel Performance

Celemics has established the design technologies for the probes and reagents for various applications and achieved superior uniformity and depth of coverage compared to competitor products.



\* Target region of both panels (BED file) are identical.  
\* Same number of reads are plotted for both panels.

## Publications

### Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses

*Hepatology* (2021) Yoon JG et al.; doi: 10.1002/hep.31862. Epub ahead of print. PMID: 33884649.

"The obtained tumor samples were sequenced with a targeted panel of three different sequencing platforms including Cancer Master (CM 524; Celemics, Seoul, Republic of Korea), TruSight Tumor 170 (TST 170; Illumina, CA, USA), and TruSight Oncology 500 (TSO 500; Illumina, CA, USA; Table S1)."

### Targeted next-generation sequencing-based detection of microsatellite instability in colorectal carcinomas

*PLoS One* (2021) Lee Y et al.;16(2):e0246356.

"Custom RNA probes were designed for target enrichment sequencing (Celemics Inc, Seoul, Korea) and covered all unions of reported exons of 50 genes (total count of regions was 753)... Capture probes were hybridized in buffer to capture target regions of the C5 gene through the use of the Celemics Target Enrichment Kit."

### Development and validation of a next-generation sequencing-based multigene assay to predict the prognosis of estrogen receptor-positive, HER2-negative breast cancer

*Clin Cancer Res.* (2020) Lee HB et al.;26(24):6513-6522.

"DNA fragments in the library were then hybridized with 179 gene probes, and target capture and amplification of the captured library were carried out with the Target Capture Solution Box #1, #2, and #3 (Celemics Inc., Seoul, South Korea) and target capture probes synthesized by Celemics Inc. Each captured library was then validated ..."

### Anaplastic Thyroid Cancer Arising from Dysrhormonogenetic Goiter: c.3070T>C and Novel c.7070T>C Mutation in the Thyroglobulin Gene

*Thyroid* (2020) Yoon JH et al.;30(11):1676-1680.

"Exomes were captured using a customized Target Enrichment System Kit (Celemics, Seoul, Korea). Genomic DNA was extracted from peripheral blood sample and targeted gene sequencing was performed with Miseq Platform ..."

### Spontaneous mutations in the single TTN gene represent high tumor mutation burden

*NPJ Genom Med.* (2020) Oh JH et al. 14:5:33.

"For the AMC cohort (24 CRCs) with NGS data, a TTN gene panel (Celemics, Korea) was designed to cover only the exonic regions of the TTN gene. Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue, ..."

### p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

*Br J Cancer* (2019) Oh HJ et al. Apr;120(8):797-805.

"Of the 621 cases, 469 cases were included in our previous study in which targeted exome sequencing of 40 genes was performed using a HiSeq2500 (Illumina, USA) by Celemics, Inc. (Seoul, South Korea)."

## Contact us

Celemics, Inc.

19F ~ 20F, Bldg. A, BYC Highcity, 131, Gasandigital 1-ro, Geumcheon-gu, Seoul, 08506, Korea

E-mail. [cs@celemics.com](mailto:cs@celemics.com)  
Web. [www.celemics.com](http://www.celemics.com)

Tel. +82-2-6746-8067  
Fax. +82-2-6746-8073

